Fig. 2From: Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphomaRenal function during R-DHAP treatment by stage. GFR and corresponding renal function by stage during the course of therapy is shown separately for every single patient who underwent one (a, n = 31), two (b, n = 61), three (c, n = 14) or four (d, n = 16) cycles of R-DHAPBack to article page